Jana Phillips, Honey E. East, Sarah E. French, Eugen Melcescu, Robert D. Hamilton, William C. Nicholas, Jonathan F. Fratkin, Andrew D. Parent, Gustavo Luzardo, Christian A. Koch
INTRODUCTION: Malignant prolactinoma is an exceedingly rare endocrine tumor and cannot be diagnosed on histological grounds alone. Similarly to other neuroendocrine tumors such as pheochromocytoma, the mitoses index, Ki-67, p53, and others are utilized in helping understand …
Mussa H. Almalki, Nora Nasser Aljoaib, Maha Jurais Alotaibi, Bayan Saloum Aldabas, Tayba Saleh Wahedi, Maswood M. Ahmad, Fahad Alshahrani
Pituitary tumors represent 10-15% of all intracranial tumors; of these, prolactinomas account for 40-50% of cases. Prolactinomas usually respond well to dopamine agonists (DA) as first-line therapy. However, treatment resistance remains a concern. Temozolomide (TMZ) is an oral alkylating agent that has shown promise in treating aggressive pituitary adenomas and carcinomas …
Olga Moshkin, Luis V. Syro, Bernd W. Scheithauer, Leon D. Ortiz, Camilo E. Fadul, Humberto Uribe, Ricardo Gonzalez, Michael Cusimano, Eva Horvath, Fabio Rotondo, Kalman Kovacs
Temozolomide (TMZ) has recently been recommended as a novel approach in the management of aggressive pituitary tumors. Herein, we present the case of a 43-year-old man with a 20-year history of silent subtype 2 pituitary corticotroph adenoma. Nine surgical resections and radiotherapy had failed to provide a cure. Morphological evaluation of the tumor revealed …
Filippo Ceccato, Gianluca Occhi, Daniela Regazzo, Maria Luigia Randi, Diego Cecchin, Marina Paola Gardiman, Renzo Manara, Giuseppe Lombardi, Luca Denaro, Franco Mantero, Carla Scaroni
BACKGROUND: Most pituitary adenomas with FSH- or LH-positive immunohistochemistry are endocrinologically silent, and neurological symptoms due to their large volume are the first clinical signs; they are rarely reported to be secreting gonadotropins, this usually occurring in cases with clinical endocrine findings …
Luis V. Syro, Bernd W. Scheithauer, Leon D. Ortiz, Camilo E. Fadul, Eva Horvath, Fabio Rotondo, Kalman Kovacs
The patient was a 70-year-old man with a recurrent pituitary tumor. Three surgeries were performed but the tumor recurred. Based on histologic, immunohistochemical and ultrastructural studies, the diagnosis of oncocytic gonadotrophic pituitary adenoma was made. The tumor was a macroadenoma partly immunopositive for LH …